Teva Pharmaceutical’s deutetrabenazine for the treatment of tics in pediatric patients with moderate to severe Tourette Syndrome did not meet the primary endpoint in the Phase II/III ARTISTS 1 and Phase III ARTISTS 2 trials.
Clarivate Analytics pegged 11 drugs set to enter the market during 2020 as potential blockbusters by 2024
Researchers discovered the remains of a dinosaur from what is now modern Alberta, Canada that contains evidence of having suffered a condition similar to a rare cancer of the bone marrow.
Gilead Sciences’ remdesivir is being evaluated as a treatment for Covid-19, but there are reports that the company and health authorities in China are having difficulties recruiting eligible patients.
French drugmaker Sanofi is working with a U.S. government agency to develop a vaccine against the new coronavirus from China, with a potential candidate ready for clinical trials within a year.
Researchers at the University of Helsinki identified a molecule called BT13 that potentially can increase levels of dopamine.
Recently published research in the journal ACS Chemical Neuroscience describe some new compounds that show promise as treatment for brain-eating amoebae.
Treatment with Stelara is resulting in positive outcomes for patients with Crohn’s disease, as Janssen Pharmaceutical said 79% of patients in a late-stage trial showed a clinical response to the medication and 67% were in clinical remission.
A Phase III trial is planned after promising results were revealed from Dana-Farber Cancer Institute for MK-6482 in advanced clear cell kidney cancer.
Dendreon Pharmaceuticals released results of a first-of-its-kind study examining survival outcomes in men with metastatic castrate-resistant prostate cancer who were treated with PROVENGE (sipuleucel-T) and oral agents in a real-world treatment setting.
